As of June 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $78.1 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2024 will be sufficient to fund its operations through the end of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vyne Therapeutics Inc (VYNE) Q2 Earnings Cheat Sheet
- VYNE Therapeutics announces granting of composition of matter patent for VYN202
- VYNE Therapeutics announces appointment of Banerjee as SVP
- VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue